Year: 2020

news_6

Samsung Bioepis Announces US Launch of ONTRUZANT® (trastuzumab-dttb) for Early and Metastatic HER2-overexpressing Breast Cancer and Metastatic Gastric Cancer

ONTRUZANT® is Samsung Bioepis’ first oncology biosimilar available in the United States INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. announced today...